These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 16706957)
1. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. Vischer UM J Thromb Haemost; 2006 Jun; 4(6):1186-93. PubMed ID: 16706957 [TBL] [Abstract][Full Text] [Related]
2. Relative importance of the glycoprotein Ib-binding domain and the RGD sequence of von Willebrand factor for its interaction with endothelial cells. Perrault C; Lankhof H; Pidard D; Kerbiriou-Nabias D; Sixma JJ; Meyer D; Baruch D Blood; 1997 Sep; 90(6):2335-44. PubMed ID: 9310484 [TBL] [Abstract][Full Text] [Related]
3. von Willebrand factor and its relevance to cardiovascular disorders. Lip GY; Blann AD Br Heart J; 1995 Dec; 74(6):580-3. PubMed ID: 8541159 [TBL] [Abstract][Full Text] [Related]
4. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Lip GY; Blann A Cardiovasc Res; 1997 May; 34(2):255-65. PubMed ID: 9205537 [TBL] [Abstract][Full Text] [Related]
6. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor. Hoylaerts MF Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916 [TBL] [Abstract][Full Text] [Related]
7. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients. Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318 [TBL] [Abstract][Full Text] [Related]
8. Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target. Gragnano F; Golia E; Natale F; Bianchi R; Pariggiano I; Crisci M; Diana V; Fimiani F; Limongelli G; Russo M; Cirillo P; Calabrò P Curr Vasc Pharmacol; 2017; 15(5):404-415. PubMed ID: 28155617 [TBL] [Abstract][Full Text] [Related]
9. Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb/IIIa interaction. Wu YP; Vink T; Schiphorst M; van Zanten GH; IJsseldijk MJ; de Groot PG; Sixma JJ Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1661-7. PubMed ID: 10845886 [TBL] [Abstract][Full Text] [Related]
10. Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination. Matsui T; Hori A; Hamako J; Matsushita F; Ozeki Y; Sakurai Y; Hayakawa M; Matsumoto M; Fujimura Y J Thromb Haemost; 2017 Mar; 15(3):538-548. PubMed ID: 28071872 [TBL] [Abstract][Full Text] [Related]
11. Association between brain-derived neurotrophic factor and von Willebrand factor levels in patients with stable coronary artery disease. Jin H; Chen Y; Wang B; Zhu Y; Chen L; Han X; Ma G; Liu N BMC Cardiovasc Disord; 2018 Feb; 18(1):23. PubMed ID: 29409455 [TBL] [Abstract][Full Text] [Related]
12. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. Polatli M; Cakir A; Cildag O; Bolaman AZ; Yenisey C; Yenicerioglu Y J Thromb Thrombolysis; 2008 Oct; 26(2):97-102. PubMed ID: 17622488 [TBL] [Abstract][Full Text] [Related]
13. Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality. Castaman G; Federici AB Semin Thromb Hemost; 2016 Jul; 42(5):478-82. PubMed ID: 27148840 [TBL] [Abstract][Full Text] [Related]
14. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Marx I; Christophe OD; Lenting PJ; Rupin A; Vallez MO; Verbeuren TJ; Denis CV Blood; 2008 Aug; 112(3):603-9. PubMed ID: 18487513 [TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor in type 1 diabetes: its production and coronary artery calcification. Chan NN; Fuller JH; Rubens M; Colhoun HM Med Sci Monit; 2003 Jul; 9(7):CR297-303. PubMed ID: 12883448 [TBL] [Abstract][Full Text] [Related]
16. Role of 14-3-3ζ in platelet glycoprotein Ibα-von Willebrand factor interaction-induced signaling. Zhang W; Zhao L; Liu J; Du J; Yan R; Dai K Int J Mol Sci; 2012; 13(5):5364-5374. PubMed ID: 22754302 [TBL] [Abstract][Full Text] [Related]
17. Dual roles of fucoidan-GPIbα interaction in thrombosis and hemostasis: implications for drug development targeting GPIbα. Shen C; Mackeigan DT; Shoara AA; Xu R; Bhoria P; Karakas D; Ma W; Cerenzia E; Chen Z; Hoard B; Lin L; Lei X; Zhu G; Chen P; Johnson PE; Ni H J Thromb Haemost; 2023 May; 21(5):1274-1288. PubMed ID: 36732162 [TBL] [Abstract][Full Text] [Related]
19. Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb). Patzke J; Favaloro EJ Methods Mol Biol; 2017; 1646():453-460. PubMed ID: 28804847 [TBL] [Abstract][Full Text] [Related]
20. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Lei X; Reheman A; Hou Y; Zhou H; Wang Y; Marshall AH; Liang C; Dai X; Li BX; Vanhoorelbeke K; Ni H Thromb Haemost; 2014 Feb; 111(2):279-89. PubMed ID: 24172860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]